I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 5 studies | 20% ± 5% | |
| ciliated cell | 3 studies | 19% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 5 studies | 20% ± 5% | |
| ciliated cell | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of INHBB at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 90% | 1296.84 | 221 / 245 | 97% | 46.43 | 488 / 502 |
| breast | 100% | 6739.92 | 459 / 459 | 86% | 43.97 | 964 / 1118 |
| thymus | 100% | 3427.83 | 652 / 653 | 83% | 135.47 | 504 / 605 |
| liver | 66% | 730.27 | 150 / 226 | 84% | 39.20 | 341 / 406 |
| brain | 48% | 343.02 | 1257 / 2642 | 79% | 18.22 | 555 / 705 |
| lung | 61% | 607.92 | 351 / 578 | 59% | 23.15 | 687 / 1155 |
| uterus | 82% | 1015.86 | 140 / 170 | 34% | 11.19 | 157 / 459 |
| bladder | 76% | 1158.38 | 16 / 21 | 31% | 9.10 | 155 / 504 |
| kidney | 38% | 460.29 | 34 / 89 | 64% | 51.46 | 574 / 901 |
| adrenal gland | 50% | 417.29 | 128 / 258 | 52% | 17.25 | 119 / 230 |
| skin | 80% | 1803.24 | 1450 / 1809 | 20% | 5.00 | 95 / 472 |
| adipose | 100% | 6907.91 | 1202 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 20% | 278.25 | 36 / 180 | 78% | 40.11 | 337 / 430 |
| pancreas | 24% | 239.02 | 80 / 328 | 71% | 14.61 | 127 / 178 |
| esophagus | 42% | 476.15 | 601 / 1445 | 47% | 17.45 | 86 / 183 |
| blood vessel | 72% | 884.69 | 961 / 1335 | 0% | 0 | 0 / 0 |
| stomach | 38% | 311.14 | 136 / 359 | 32% | 15.34 | 92 / 286 |
| muscle | 65% | 872.00 | 518 / 803 | 0% | 0 | 0 / 0 |
| intestine | 30% | 321.16 | 293 / 966 | 31% | 8.95 | 161 / 527 |
| heart | 38% | 378.01 | 325 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 12% | 95.49 | 113 / 929 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 7% | 1.76 | 3 / 45 |
| eye | 0% | 0 | 0 / 0 | 6% | 0.62 | 5 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.33 | 1 / 29 |
| spleen | 2% | 17.70 | 4 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0097190 | Biological process | apoptotic signaling pathway |
| GO_0032924 | Biological process | activin receptor signaling pathway |
| GO_0060279 | Biological process | positive regulation of ovulation |
| GO_0007283 | Biological process | spermatogenesis |
| GO_0032869 | Biological process | cellular response to insulin stimulus |
| GO_0045444 | Biological process | fat cell differentiation |
| GO_0001541 | Biological process | ovarian follicle development |
| GO_1904017 | Biological process | cellular response to Thyroglobulin triiodothyronine |
| GO_0097067 | Biological process | cellular response to thyroid hormone stimulus |
| GO_0071347 | Biological process | cellular response to interleukin-1 |
| GO_0072520 | Biological process | seminiferous tubule development |
| GO_0032686 | Biological process | negative regulation of hepatocyte growth factor production |
| GO_0009267 | Biological process | cellular response to starvation |
| GO_0046676 | Biological process | negative regulation of insulin secretion |
| GO_0071277 | Biological process | cellular response to calcium ion |
| GO_0046882 | Biological process | negative regulation of follicle-stimulating hormone secretion |
| GO_0048599 | Biological process | oocyte development |
| GO_0071320 | Biological process | cellular response to cAMP |
| GO_0044320 | Biological process | cellular response to leptin stimulus |
| GO_0030154 | Biological process | cell differentiation |
| GO_0071397 | Biological process | cellular response to cholesterol |
| GO_0046881 | Biological process | positive regulation of follicle-stimulating hormone secretion |
| GO_0021983 | Biological process | pituitary gland development |
| GO_2001235 | Biological process | positive regulation of apoptotic signaling pathway |
| GO_0009611 | Biological process | response to wounding |
| GO_0044650 | Biological process | adhesion of symbiont to host cell |
| GO_0017085 | Biological process | response to insecticide |
| GO_0034698 | Biological process | response to gonadotropin |
| GO_0006952 | Biological process | defense response |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0048471 | Cellular component | perinuclear region of cytoplasm |
| GO_0071944 | Cellular component | cell periphery |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0005179 | Molecular function | hormone activity |
| GO_0046789 | Molecular function | host cell surface receptor binding |
| GO_0008083 | Molecular function | growth factor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0005125 | Molecular function | cytokine activity |
| Gene name | INHBB |
| Protein name | Inhibin beta B chain (Activin beta-B chain) INHBB protein |
| Synonyms | |
| Description | FUNCTION: Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins. |
| Accessions | ENST00000295228.4 A0PK08 P09529 |
